» Articles » PMID: 38395786

An Immunogenic Cell Death-related Gene Expression Signature in Predicting Prognosis of Pancreatic Ductal Adenocarcinoma

Overview
Journal BMC Genomics
Publisher Biomed Central
Specialty Genetics
Date 2024 Feb 23
PMID 38395786
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immunogenic cell death (ICD) has been identified as regulated cell death, which is sufficient to activate the adaptive immune response. This study aimed to research ICD-related genes and create a gene model to predict pancreatic ductal adenocarcinoma (PAAD) patients' prognosis.

Methods: The RNA sequencing and clinical data were downloaded from the TGCA and GEO databases. The PAAD samples were classified into two subtypes based on the expression levels of ICD-related genes using consensus clustering. Based on the differentially expressed genes (DEGs), a prognostic scoring model was constructed using LASSO regression and Cox regression, and the scoring model was used to predict the prognosis of PAAD patients. Moreover, colony formation assay was performed to confirm the prognostic value of those genes.

Results: We identified two ICD cluster by consensus clustering, and found that the the ICD-high group was closely associated with immune-hot phenotype, favorable clinical outcomes. We established an ICD-related prognostic model which can predict the prognosis of pancreatic ductal adenocarcinoma. Moreover, depletion of NT5E, ATG5, FOXP3, and IFNG inhibited the colony formation ability of pancreatic cancer cell.

Conclusion: We identified a novel classification for PAAD based on the expression of ICD-related genes, which may provide a potential strategy for therapeutics against PAAD.

Citing Articles

Classification patterns identification of immunogenic cell death-related genes in heart failure based on deep learning.

Ma Z, Ma S, Chen B, Zhang Y, Zeng J, Tao J Sci Rep. 2025; 15(1):5633.

PMID: 39955386 PMC: 11829947. DOI: 10.1038/s41598-025-89333-1.


Construction and validation of immunogenic cell death-related molecular clusters, signature, and immune landscape in pancreatic cancer.

Hu C, Yin Y, Xu D, Xu Y, Yang J, Xu Y Clin Exp Med. 2024; 25(1):19.

PMID: 39708151 PMC: 11663176. DOI: 10.1007/s10238-024-01533-7.

References
1.
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

2.
Hruban R, Wilentz R, Kern S . Genetic progression in the pancreatic ducts. Am J Pathol. 2000; 156(6):1821-5. PMC: 1850064. DOI: 10.1016/S0002-9440(10)65054-7. View

3.
Kamisawa T, Wood L, Itoi T, Takaori K . Pancreatic cancer. Lancet. 2016; 388(10039):73-85. DOI: 10.1016/S0140-6736(16)00141-0. View

4.
Afghani E, Klein A . Pancreatic Adenocarcinoma: Trends in Epidemiology, Risk Factors, and Outcomes. Hematol Oncol Clin North Am. 2022; 36(5):879-895. PMC: 10548451. DOI: 10.1016/j.hoc.2022.07.002. View

5.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View